---
schema_version: "secwatch.filing_event.v1"
accession: "0001725160-24-000177"
form_type: "8-K"
ticker: "ZNTL"
cik: "0001725160"
company_name: "Zentalis Pharmaceuticals, Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T00:59:10.347595+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Zentalis appoints Julie Eastland CEO, succeeding Blackwell; plans registrational studies for azenosertib

## Summary
- Julie Eastland appointed CEO, President and Director effective Nov 13, 2024; succeeds Kimberly Blackwell who resigned as CEO but remains strategic advisor.
- Ingmar Bruns appointed Chief Medical Officer; Scott Myers appointed Board Chairperson.
- Cam Gallagher resigned as President/Interim CFO; Vincent Vultaggio named interim principal financial officer.
- Board approved amendment to 2022 Inducement Plan, increasing available shares by 5,500,000.
- Company plans to host investor event in Jan 2025 with updated azenosertib data and regulatory update.

## SEC filing metadata
- accession: 0001725160-24-000177
- form_type: 8-K
- ticker: ZNTL
- cik: 0001725160
- company_name: Zentalis Pharmaceuticals, Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725160/000172516024000177/0001725160-24-000177-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725160/000172516024000177/zntl-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001725160-24-000177
- JSON: https://secwatch.observer/filing/0001725160-24-000177.json
- Plain text: https://secwatch.observer/filing/0001725160-24-000177.txt

## Key facts
- Executive change
  Julie Eastland was appointed as Chief Executive Officer, President and a Class I director at Zentalis Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Chief Executive Officer, President and a Class I director
  source text: On November 12, 2024, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) appointed Julie Eastland as Chief Executive Officer, President and a Class I director of the Company with an initial term scheduled to expire at the Company’s 2027 Annual Meeting of Stockholders, in each case effective November 13, 2024 (the “Transition Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1725160/000172516024000177/0001725160-24-000177-index.htm
- Executive change
  Kimberly Blackwell resigned as Chief Executive Officer and Director at Zentalis Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Chief Executive Officer and Director
  source text: Also on November 12, 2024, Kimberly Blackwell, M.D., resigned as Chief Executive Officer, a member of the Board and from all other positions held with the Company and its affiliates, effective on the Transition Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1725160/000172516024000177/0001725160-24-000177-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.